Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
12 February 2021Website:
http://www.neximmune.comNext earnings report:
15 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:52:43 GMTDividend
Analysts recommendations
Institutional Ownership
NEXI Latest News
Shares of NexImmune (NASDAQ: NEXI ) stock are skyrocketing higher ahead of the company's special meeting of stockholders. The meeting was initially set for Dec. 21 with a record date of Nov. 6.
Inexplicably, shares of embattled immunotherapy specialist NexImmune (NASDAQ: NEXI ) are skyrocketing more than 190% despite efforts to dissolve the business. An earlier attempt to vote on the liquidation and dissolution of the biotechnology enterprise failed due to a lack of quorum.
Following a dramatic spike in shares yesterday, exchange operators at Nasdaq pulled the circuit breaker on NexImmune (NASDAQ: NEXI ). Though seemingly offering innovative solutions to disease treatment, the biotechnology firm has lost almost all its value since its initial public offering in 2021.
NexImmune (NASDAQ: NEXI ) stock is heading higher on Friday despite a lack of news from the clinical-stage biotechnology company. There are no new press releases for filings with the Securities and Exchange Commission (SEC) that help explain why NEXI stock is up today.
What type of business is NexImmune?
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
What sector is NexImmune in?
NexImmune is in the Healthcare sector
What industry is NexImmune in?
NexImmune is in the Biotechnology industry
What country is NexImmune from?
NexImmune is headquartered in United States
When did NexImmune go public?
NexImmune initial public offering (IPO) was on 12 February 2021
What is NexImmune website?
https://www.neximmune.com
Is NexImmune in the S&P 500?
No, NexImmune is not included in the S&P 500 index
Is NexImmune in the NASDAQ 100?
No, NexImmune is not included in the NASDAQ 100 index
Is NexImmune in the Dow Jones?
No, NexImmune is not included in the Dow Jones index
When does NexImmune report earnings?
The next expected earnings date for NexImmune is 15 August 2024